An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. (2nd January 2023)

• Record Type: Journal Article
• Authors: Cipriani, Sarah; Alfaroli, Chiara; Maseroli, Elisa; Vignozzi, Linda
• Is Part Of: Expert opinion on pharmacotherapy. Volume 24:Number 1(2023)
• Page Start: 15
• Page End: 21
• Publication Date: 2023-01-02
• Subjects: Female sexual dysfunction -- bremelanotide -- hypoactive sexual desire disorder -- female sexual distress; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2022.2132144
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Female sexual response implies a deep intertwining between psychosocial and neurobiological mediators. Regulation of central melanocortin signaling may enhance sexual desire. In premenopausal women with hypoactive sexual desire disorder (HSDD), melanocortin receptor agonist bremelanotide (Vyleesi) has been hypothesized to trigger excitatory brain pathways. Areas covered: Hereby we summarize bremelanotide's proposed mechanism of action, pharmacokinetics, efficacy and safety data derived from clinical trials. A literature search of peer-reviewed publications on the current evidence on the pharmacotherapy with bremelanotide was performed using the PubMed database. Expert opinion: Bremelanotide appears to be moderately safe and well-tolerated; the most common adverse reaction is nausea (40%). Although data from clinical trials demonstrated a significant change in validated questionnaires, the overall clinical benefit appears to be modest. However, these results should be interpreted in the light of the dramatic challenges in conducting well-designed clinical trials for female sexual dysfunction, due to the significant placebo effect of pharmacotherapy, and the frequent use of outcome measures that are likely to be highly susceptible to expectation biases, such as long periods of recall of sexual and emotional response.